Added to YB: 2025-02-05
Pitch date: 2024-12-19
BBIO [bullish]
BridgeBio Pharma, Inc.
+169.89%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Market Cap
$13.4B
Pitch Price
$26.04
Price Target
76.23 (+8%)
Dividend
N/A
EV/EBITDA
-26.55
P/E
-18.32
EV/Sales
25.86
Sector
Biotechnology
Category
growth
Show full summary:
BridgeBio Pharma, Inc. - $BBIO
BBIO: FDA-approved Attruby for ATTR-CM, $2B peak sales potential by 2028. 3 key Phase 3 readouts in 2025: encaleret (ADH1), BBP-418 (LGMD2I/R9), infigratinib (achondroplasia). $406M cash, $500M milestone. Risks: clinical failures, competition from Pfizer/Alnylam. Bull case: $76.23/share
Read full article (4 min)